Health Care · Life Sciences Tools & Services
Charles River Laboratories: revenue, profit and cash flow
In fiscal 2025, Charles River Laboratories had revenue of $4.02B, up 11.4% a year on average since 2015, and a net loss of $144M.
Revenue, fiscal 2025
average annual revenue growth since 2015 · −0.9% vs 2024
- Ticker
- CRL · NYSE
- Sector
- Health Care
- Sub-industry
- Life Sciences Tools & Services
- Headquarters
- Wilmington, Massachusetts
- Founded
- 1947
- In the S&P 500 since
- May 14, 2021
- Latest fiscal year
- 2025, ended December 27, 2025
- SEC filer
- Charles River Laboratories International, Inc. · CIK 0001100682
Revenue and net income
Revenue went from $1.3B in 2008 to $4.02B in 2025. Net loss in 2008, 2010, 2025.
Diluted earnings per share
Diluted EPS went from −$7.80 in 2008 to −$2.91 in 2025.
Shares outstanding
4.1% more shares in 2025 than in 2015 (47.6M → 49.6M): new shares outweighed buybacks.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $518M in 2025, 12.9% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|
| 2025 | $4.02B | −$144M | −3.6% | −$2.91 | 49.6M | $738M | $219M | $518M |
| 2024 | $4.05B | $22.2M | 0.5% | $0.20 | 51.6M | $735M | $233M | $502M |
| 2023 | $4.13B | $475M | 11.5% | $9.22 | 51.5M | $684M | $319M | $365M |
| 2022 | $3.98B | $486M | 12.2% | $9.48 | 51.3M | $620M | $325M | $295M |
| 2021 | $3.54B | $391M | 11.0% | $7.60 | 51.4M | $761M | $229M | $532M |
| 2020 | $2.92B | $364M | 12.5% | $7.20 | 50.6M | $547M | $167M | $380M |
| 2019 | $2.62B | $252M | 9.6% | $5.07 | 49.7M | $481M | $141M | $340M |
| 2018 | $2.27B | $226M | 10.0% | $4.62 | 49M | $441M | $140M | $301M |
| 2017 | $1.86B | $123M | 6.6% | $2.54 | 48.6M | $318M | $82.4M | $236M |
| 2016 | $1.68B | $155M | 9.2% | $3.23 | 48M | $317M | $55.3M | $262M |
| 2015 | $1.36B | $149M | 11.0% | $3.13 | 47.6M | $307M | $63.3M | $244M |
| 2014 | $1.3B | $127M | 9.8% | $2.66 | 47.6M | $252M | $56.9M | $195M |
| 2013 | $1.17B | $103M | 8.8% | $2.12 | 48.5M | $209M | $39.2M | $170M |
| 2012 | $1.13B | $97.3M | 8.6% | $2.01 | 48.4M | $208M | $47.5M | $160M |
| 2011 | $1.14B | $110M | 9.6% | $2.14 | 51.3M | $207M | $49.1M | $158M |
| 2010 | $1.13B | −$337M | −29.7% | −$5.38 | 62.6M | $168M | $42.9M | $125M |
| 2009 | $1.17B | $114M | 9.8% | $1.74 | 65.6M | $216M | $79.9M | $136M |
| 2008 | $1.3B | −$525M | −40.5% | −$7.80 | — | $276M | $199M | $76.9M |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- No dividends per share in the filings data. Usually that means no dividend, but some companies report theirs in a form the data do not capture.
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Life Sciences Tools & Services companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.